156 related articles for article (PubMed ID: 34257721)
1. PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines.
Li Y; Sharma A; Bloemendal MWJR; Schmidt-Wolf R; Kornek M; Schmidt-Wolf IGH
Oncol Lett; 2021 Aug; 22(2):613. PubMed ID: 34257721
[TBL] [Abstract][Full Text] [Related]
2. Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer.
Chen J; Chen Y; Feng F; Chen C; Zeng H; Wen S; Xu X; He J; Li J
J Thorac Dis; 2018 Dec; 10(12):6711-6721. PubMed ID: 30746216
[TBL] [Abstract][Full Text] [Related]
3. A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.
Li Y; Sharma A; Wu X; Weiher H; Skowasch D; Essler M; Schmidt-Wolf IGH
Front Oncol; 2022; 12():713476. PubMed ID: 35646685
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.
Poh SL; Linn YC
Cancer Immunol Immunother; 2016 May; 65(5):525-36. PubMed ID: 26961084
[TBL] [Abstract][Full Text] [Related]
5. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
6. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies.
Pievani A; Belussi C; Klein C; Rambaldi A; Golay J; Introna M
Blood; 2011 Jan; 117(2):510-8. PubMed ID: 21048157
[TBL] [Abstract][Full Text] [Related]
7. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.
Dai C; Lin F; Geng R; Ge X; Tang W; Chang J; Wu Z; Liu X; Lin Y; Zhang Z; Li J
Oncotarget; 2016 Mar; 7(9):10332-44. PubMed ID: 26871284
[TBL] [Abstract][Full Text] [Related]
8. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of cytokine-induced killer cells targeting CD40 and GITR.
Biederbick KD; Schmidt-Wolf IGH
Oncol Lett; 2019 Feb; 17(2):2425-2430. PubMed ID: 30675308
[TBL] [Abstract][Full Text] [Related]
10. Blocking the PD-1/PD-L1 axis in dendritic cell-stimulated Cytokine-Induced Killer Cells with pembrolizumab enhances their therapeutic effects against hepatocellular carcinoma.
Zhang W; Song Z; Xiao J; Liu X; Luo Y; Yang Z; Luo R; Li A
J Cancer; 2019; 10(11):2578-2587. PubMed ID: 31258764
[TBL] [Abstract][Full Text] [Related]
11. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
[TBL] [Abstract][Full Text] [Related]
12. Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.
Chen CL; Pan QZ; Weng DS; Xie CM; Zhao JJ; Chen MS; Peng RQ; Li DD; Wang Y; Tang Y; Wang QJ; Zhang ZL; Zhang XF; Jiang LJ; Zhou ZQ; Zhu Q; He J; Liu Y; Zhou FJ; Xia JC
Oncoimmunology; 2018; 7(4):e1417721. PubMed ID: 29632736
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death Receptor 1 (PD1) Knockout and Human Telomerase Reverse Transcriptase (hTERT) Transduction Can Enhance Persistence and Antitumor Efficacy of Cytokine-Induced Killer Cells Against Hepatocellular Carcinoma.
Huang K; Sun B; Luo N; Guo H; Hu J; Peng J
Med Sci Monit; 2018 Jul; 24():4573-4582. PubMed ID: 29967316
[TBL] [Abstract][Full Text] [Related]
14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
15. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD20 antibody induces the improvement of cytokine-induced killer cell activity via the STAT and MAPK/ERK signaling pathways.
Deng QI; Bai X; Lv HR; Xiao X; Zhao MF; Li YM
Exp Ther Med; 2015 Apr; 9(4):1215-1222. PubMed ID: 25780412
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
18. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.
Rettinger E; Kuçi S; Naumann I; Becker P; Kreyenberg H; Anzaghe M; Willasch A; Koehl U; Bug G; Ruthardt M; Klingebiel T; Fulda S; Bader P
Cytotherapy; 2012 Jan; 14(1):91-103. PubMed ID: 21973023
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells.
Huang F; Wang B; Zeng J; Sang S; Lei J; Lu Y
Oncol Lett; 2018 Apr; 15(4):4797-4804. PubMed ID: 29552119
[TBL] [Abstract][Full Text] [Related]
20. Increase of Antitumoral Effects of Cytokine-Induced Killer Cells by Antibody-Mediated Inhibition of MICA Shedding.
Wu X; Zhang Y; Li Y; Schmidt-Wolf IGH
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32645836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
